Related Experiment Video

Updated: May 7, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2

Bohua Li1, Yanchun Meng, Lei Zheng

  • 1Authors' Affiliations: International Joint Cancer Institute, the Second Military Medical University; National Engineering Research Center for Antibody Medicine; State Key Laboratory of Antibody Medicine and Targeted Therapy; School of Medicine, Shanghai Jiao Tong University, Shanghai; and PLA General Hospital Cancer Center, PLA Postgraduate Medical School, Beijing, People's Republic of China.

Cancer Research
|September 19, 2013
PubMed

Insights

A new bispecific antibody, TPL, effectively overcomes trastuzumab resistance in breast cancer by blocking ErbB2 signaling. TPL demonstrated superior efficacy in preclinical models compared to existing therapies.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Trastuzumab is a key therapy for ErbB2-positive metastatic breast cancer, but resistance is a significant clinical challenge.
  • ErbB2 heterodimerization with other ErbB family members can drive cell proliferation and contribute to trastuzumab resistance.

Purpose of the Study:

  • To develop and evaluate a bispecific antibody (TPL) combining trastuzumab and pertuzumab to overcome trastuzumab resistance.
  • To investigate TPL's mechanism of action in blocking ErbB2 heterodimerization and signaling.

Main Methods:

  • Development of a bispecific antibody (TPL) by linking trastuzumab and pertuzumab.
  • Assessment of TPL's binding activity, pharmacokinetics, and ErbB2 heterodimerization-blocking capacity.
  • Evaluation of TPL's efficacy in inhibiting ErbB2 signaling and tumor growth in trastuzumab-resistant breast cancer models (in vitro and in vivo).

Main Results:

  • TPL retained parental antibody binding and exhibited favorable pharmacokinetics.
  • TPL demonstrated superior ErbB2 heterodimerization inhibition compared to the combination of trastuzumab and pertuzumab.
  • TPL effectively abrogated ErbB2 signaling, inhibited tumor growth, and eradicated established tumors in trastuzumab-resistant models.

Conclusions:

  • Comprehensive blockade of ErbB2 heterodimerization is a viable strategy to overcome trastuzumab resistance in breast cancer.
  • The bispecific antibody TPL shows significant potential as a novel therapeutic agent for trastuzumab-resistant breast tumors.

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...